Tenderwize
Retour à la recherche

Open-house rebate agreement for Solifenacin/Tamsulosin

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Feb 29, 2028 · 550 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Solifenacin/Tamsulosin (ATC-Code nach WHO: G04CA53)

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

The notice says participation applications can be submitted electronically via DTVP, but also states that some portal i...

Demand is unknown and minimum purchase quantities are not guaranteed, so revenue volume is uncertain.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2028
  • Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Solifenacin/Tamsulosin.
  • Open-House participation model with no individual contract negotiations.
Afficher le résumé complet

This is an Open-House supply arrangement for non-exclusive pharmaceutical rebate agreements for Solifenacin/Tamsulosin (ATC G04CA53) led by AOK PLUS. Any interested pharmaceutical company may join during the participation period if it meets and accepts the stated conditions. No individual negotiations or supply exclusivity apply. The contract term ends no later than 2028-02-29. Participation is handled electronically via DTVP project space, but the submission method is described as technically constrained and not fully consistent across the notice data.

Risques

The notice says participation applications can be submitted electronically via DTVP, but also states that some portal i...

Demand is unknown and minimum purchase quantities are not guaranteed, so revenue volume is uncertain.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical company within the meaning of the cited German pharmaceutical law provisions for the offered medicinal product.
  • The bidder must accept the participation conditions and the rebate agreement terms.

Eligibility

  • The bidder must submit the completed declaration of non-existence of exclusion grounds under §§ 123, 124 GWB.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Solifenacin/Tamsulosin

Non-exclusive supply contract for pharmaceutical rebate agreements concerning Solifenacin/Tamsulosin (ATC G04CA53). The lot is an Open-House model, so all interested pharmaceutical companies may participate if they satisfy the participation conditions. Place of performance is Germany, specifically Dresden in Saxony/Thuringia context as stated in the notice data.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Feb 2026 - Feb 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 29, 2028

Détails de la procédure

Date de publication
22 Dec 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
856012-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30